ATE410145T1 - Herstellungsverfahren für brausegranulate - Google Patents

Herstellungsverfahren für brausegranulate

Info

Publication number
ATE410145T1
ATE410145T1 AT01927938T AT01927938T ATE410145T1 AT E410145 T1 ATE410145 T1 AT E410145T1 AT 01927938 T AT01927938 T AT 01927938T AT 01927938 T AT01927938 T AT 01927938T AT E410145 T1 ATE410145 T1 AT E410145T1
Authority
AT
Austria
Prior art keywords
granules
agent
agents
pharmacologically active
effervescent
Prior art date
Application number
AT01927938T
Other languages
English (en)
Inventor
Joseph Robinson
James Mcginity
Pascal Delmas
Original Assignee
Ethypharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Sa filed Critical Ethypharm Sa
Application granted granted Critical
Publication of ATE410145T1 publication Critical patent/ATE410145T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Disintegrating Or Milling (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01927938T 2000-04-20 2001-04-20 Herstellungsverfahren für brausegranulate ATE410145T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/553,528 US6649186B1 (en) 1996-09-20 2000-04-20 Effervescent granules and methods for their preparation

Publications (1)

Publication Number Publication Date
ATE410145T1 true ATE410145T1 (de) 2008-10-15

Family

ID=24209766

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01927938T ATE410145T1 (de) 2000-04-20 2001-04-20 Herstellungsverfahren für brausegranulate

Country Status (19)

Country Link
US (1) US6649186B1 (de)
EP (1) EP1274398B1 (de)
JP (1) JP5063848B2 (de)
KR (1) KR20030011829A (de)
CN (1) CN100337613C (de)
AT (1) ATE410145T1 (de)
AU (2) AU5482601A (de)
BG (1) BG65877B1 (de)
CA (1) CA2406833C (de)
CZ (1) CZ20023419A3 (de)
DE (1) DE60136057D1 (de)
DK (1) DK1274398T3 (de)
HU (1) HU230267B1 (de)
IL (1) IL152317A (de)
MX (1) MXPA02010338A (de)
NO (1) NO333395B1 (de)
SK (1) SK287187B6 (de)
WO (1) WO2001080822A2 (de)
ZA (1) ZA200208456B (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9311399B2 (en) 1999-09-07 2016-04-12 C. Douglass Thomas System and method for providing an updating on-line forms and registrations
US7747592B2 (en) * 1999-09-07 2010-06-29 Thomas C Douglass Method and system for monitoring domain name registrations
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2001097801A2 (en) * 2000-06-23 2001-12-27 Societe Civile Bioprojet Dry powder formulation comprising racecadotril
FR2823668B1 (fr) * 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles
CZ20033269A3 (en) * 2001-05-21 2004-03-17 H. Lundbeck A/S Granular preparations of gaboxadol
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
GB0129117D0 (en) * 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
AU2002353659A1 (en) * 2001-12-18 2003-07-15 Synthon B.V. Simvastatin dosage forms
US7233550B2 (en) 2002-09-30 2007-06-19 Lg Electronics Inc. Write-once optical disc, and method and apparatus for recording management information on write-once optical disc
TWI314315B (en) 2003-01-27 2009-09-01 Lg Electronics Inc Optical disc of write once type, method, and apparatus for managing defect information on the optical disc
US20070184109A1 (en) * 2003-06-06 2007-08-09 Floyd Alison G Compositions comprising triptans and nsaids
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
TR200301614A2 (tr) * 2003-09-26 2005-10-21 Bi̇ofarma İlaç Sanayi̇ Ve Ti̇caret A.Ş. Atorvastatin kalsiyum tablet formülasyonunun hazırlanması için yeni yöntem
WO2005044193A2 (en) * 2003-10-28 2005-05-19 Spi Pharma, Inc. Product and process for increasing compactibility of carbohydrates
CA2549642C (en) * 2003-12-31 2012-10-30 Cima Labs Inc. Effervescent oral opiate dosage forms and methods of administering opiates
WO2005065319A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
WO2005077341A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Orally disintegrating pharmaceutical compositions of ondansetron
AT500101A1 (de) * 2004-02-04 2005-10-15 Tritthart Thomas Verkapselungsprozess
KR100574554B1 (ko) * 2004-05-28 2006-04-27 한미약품 주식회사 니아신의 경구투여용 서방성 조성물
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
RU2389480C2 (ru) * 2004-08-12 2010-05-20 РЕКИТТ БЕНКАЙЗЕР ХЕЛТКЭА (Ю Кей) ЛИМИТЕД Гранулы, содержащие нпвлс и сахарный спирт, изготовленные экструзией из расплава
US20060039972A1 (en) * 2004-08-19 2006-02-23 Mary Aldritt Effervescent composition including a grape-derived component
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
MX2007002781A (es) * 2004-09-09 2009-02-12 Bayer Animal Health Gmbh Composición farmacéutica.
ES2675581T3 (es) * 2005-02-25 2018-07-11 Takeda Pharmaceutical Company Limited Método para producir gránulos de un compuesto de bencimidazol recubiertos
JP2007015966A (ja) * 2005-07-06 2007-01-25 Fujimoto Corporation:Kk 口腔内崩壊錠
CA2624943A1 (en) * 2005-10-07 2007-04-19 Colocaps Pty Ltd. Preparation for the treatment of diarrhoea
KR20080070848A (ko) * 2005-11-03 2008-07-31 레드포인트 바이오 코포레이션 히드라존 유도체 및 이의 용도
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP3263117A1 (de) 2005-11-28 2018-01-03 Imaginot Pty Ltd. Abgabesystem für eine orale therapeutische verbindung
WO2007075408A2 (en) * 2005-12-16 2007-07-05 Effrx, Inc. Effervescent compositions for triptans
MX2008012265A (es) * 2006-03-24 2009-02-20 Auxilium Int Holdings Inc Procedimiento para la preparacion de un laminado extruido por fusion en caliente.
WO2007112286A2 (en) 2006-03-24 2007-10-04 Auxilium Pharmaceuticals, Inc. Stabilized compositions containing alkaline labile drugs
BRPI0602825A2 (pt) * 2006-06-23 2012-04-24 Rhodia Br Ltda formulação de pó efervescente auto-refrigerante para bebidas e uso de formulação em pó efervescente
CN1994296B (zh) * 2006-08-02 2010-06-16 浙江京新药业股份有限公司 一种含有辛伐他汀的药物制剂
MX2009001783A (es) * 2006-08-22 2009-02-25 Redpoint Bio Corp Compuestos heterociclicos como potenciadores de edulcorantes.
WO2008033545A2 (en) * 2006-09-15 2008-03-20 Redpoint Bio Corporation Triphenylphosphine oxide derivatives and uses thereof
WO2008057300A2 (en) * 2006-10-27 2008-05-15 Redpoint Bio Corporation Trpvi antagonists and uses thereof
WO2008097504A2 (en) * 2007-02-02 2008-08-14 Redpoint Bio Corporation Use of a trpm5 inhibitor to regulate insulin and glp-1 release
CA2680238A1 (en) * 2007-07-23 2009-01-29 Teikoku Pharma Usa, Inc. Organoleptically acceptable indole serotonin receptor agonist oral dosage formulations and methods of using the same
EP2293779A1 (de) * 2008-04-24 2011-03-16 Evestra, Inc. Orale kontrazeptive dosierformen mit einem progestogen, das in einem enterischen polymer dispergiert ist, und ferner mit einem östrogen
FR2938431B1 (fr) 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
WO2010086989A1 (ja) 2009-01-29 2010-08-05 日東電工株式会社 口腔内フィルム状基剤及び製剤
US20100215758A1 (en) * 2009-02-25 2010-08-26 Joar Opheim Effervescent nutritional and/or dietary supplement composition
EP2440210A4 (de) 2009-06-12 2014-01-29 Meritage Pharma Inc Verfahren zur behandlung von magen-darm-erkrankungen
MX2011013539A (es) * 2009-06-26 2012-02-28 Taris Biomedical Inc Tabletas de farmaco solidas para dispositivos implantables para administrar farmacos.
CN101966165B (zh) * 2009-07-14 2012-06-13 无锡健而乐医药科技有限公司 口腔吸收固体泡腾制剂
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
CA2771207A1 (en) * 2009-08-17 2011-02-24 Waxtabs (Pty) Ltd Tablet manufacture
CA2773134A1 (en) 2009-09-04 2011-03-10 Redpoint Bio Corporation Sweetness enhancers including rebaudioside a or d
US20120230922A1 (en) 2009-09-22 2012-09-13 Redpoint Bio Corporation Novel Polymorphs of Rebaudioside C and Methods for Making and Using the Same
JP5751868B2 (ja) 2010-03-30 2015-07-22 日東電工株式会社 フィルム状製剤及びその製造方法
EP2571485B1 (de) * 2010-05-18 2022-02-16 Mahmut Bilgic Antihistamin-brauseformulierungen
CA2803980A1 (en) * 2010-07-01 2012-01-05 Delante Health As Coated effervescent tablet
FR2962550B1 (fr) * 2010-07-06 2013-06-14 Ethypharm Sa Methode pour lutter contre la soumission chimique, utilisation d'agent colorant pour lutter contre la soumission chimique et composition pharmaceutique permettant la mise en oeuvre de la methode
FR2962331B1 (fr) * 2010-07-06 2020-04-24 Ethypharm Forme pharmaceutique pour lutter contre la soumission chimique, methode la mettant en oeuvre
EP2929877A1 (de) * 2010-07-08 2015-10-14 ratiopharm GmbH Orale darreichungsform von deferasirox
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
CN103987840A (zh) 2011-08-08 2014-08-13 国际香料香精公司 用于香草醛或香草醛β-D-葡萄糖苷的生物合成的组合物和方法
US20150224097A1 (en) * 2011-11-22 2015-08-13 Watson Pharmaceuticals, Inc. Immediate Release Abuse Deterrent Tablet
JP5841433B2 (ja) * 2012-01-11 2016-01-13 日東電工株式会社 口腔内フィルム状基剤及び製剤
CN102525944A (zh) * 2012-01-11 2012-07-04 扬子江药业集团广州海瑞药业有限公司 枸地氯雷他定颗粒及其制备方法
EP2649989B1 (de) * 2012-04-13 2017-10-18 King Saud University Verfahren zur Herstellung einer Feststoffdispersion, damit hergestellte Feststoffdispersion und Verwendung dafür
PE20150597A1 (es) 2012-08-20 2015-05-06 Merck Patent Gmbh Preparacion farmaceutica solida que contiene levotiroxina
CN105142730B (zh) * 2013-03-15 2019-04-16 通尼克斯制药有限公司 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂
US11058642B2 (en) * 2013-04-22 2021-07-13 Tower Laboratories Ltd Tablets with improved friability
EP2880992A3 (de) 2013-12-05 2015-06-17 International Flavors & Fragrances Inc. Rebaudiosid C und dessen als Stereoisomere als Naturprodukt-Süßkraftverstärker
ES2707701T3 (es) 2014-03-28 2019-04-04 Galderma Res & Dev Espuma química no enjuagada que contiene peróxido de benzoílo
GB201411802D0 (en) * 2014-07-02 2014-08-13 Univ Bradford Effervescent compositions
CA2961445C (en) 2014-09-17 2019-03-26 Babu Padmanabhan Effervescent composition and method of making it
CN104434863B (zh) * 2014-11-13 2017-05-24 武汉大学 一种盐酸丁卡因口腔泡腾片及其制备方法
JP6682385B2 (ja) * 2015-07-01 2020-04-15 花王株式会社 固形状組成物
FR3041536B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant du trifarotene, et son utilisation dans le traitement de l'acne.
FR3041539B1 (fr) 2015-09-29 2018-10-26 Galderma Research & Development Composition nettoyante auto-moussante contenant du propionate de clobetasol, et son utilisation dans le traitement du psoriasis.
FR3041538B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant du propionate de clobetasol, et son utilisation dans le traitement du psoriasis.
FR3041537B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant de la brimonidine et son utilisation dans le traitement de la rosacee.
FR3041541B1 (fr) * 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee comprenant de l'ivermectine
FR3041535B1 (fr) 2015-09-29 2019-01-25 Galderma Research & Development Mousse chimique non rincee contenant du trifarotene, et son utilisation dans le traitement de l'ichtyose.
US11219594B2 (en) 2015-12-12 2022-01-11 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
SG11202004799TA (en) 2017-12-11 2020-06-29 Tonix Pharma Holdings Ltd Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN110075072A (zh) * 2019-05-24 2019-08-02 山东新华制药股份有限公司 一种布洛芬赖氨酸泡腾颗粒的制备方法
US20200405673A1 (en) * 2019-06-25 2020-12-31 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide
FR3099881B1 (fr) * 2019-08-13 2022-08-26 Ethypharm Sa Comprimé orodispersible d’opioide à faible dosage et son procédé de préparation.
CN114146061B (zh) * 2020-09-07 2023-06-30 歌礼生物科技（杭州）有限公司 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
US20220287303A1 (en) * 2021-03-14 2022-09-15 LMA Solutions, Inc. Compositions and methods for disinfecting removable dental appliances
CN117441898B (zh) * 2023-12-22 2024-04-12 山东天力药业有限公司 一种维生素c泡腾颗粒及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1262888A (en) 1917-02-20 1918-04-16 Albert Westlake Mouth-tablet.
GB917456A (en) 1958-10-30 1963-02-06 Casco Lab Inc Suppository composition and preparation thereof
DE1467938C3 (de) 1964-05-22 1973-12-20 F. Hoffmann-La Roche & Co Ag, Basel (Schweiz) Wasserdispergierbares Arzneipräparat für Tiere
US3667929A (en) 1969-07-30 1972-06-06 George W Fleming Jr Method of effecting dissolution of solutes in water and compositions therefor
US3962417A (en) 1974-03-27 1976-06-08 Howell Charles J Dentifrice
US4153678A (en) 1978-07-17 1979-05-08 American Cyanamid Company Levamisole effervescent tablets
US4267164A (en) 1980-01-31 1981-05-12 Block Drug Company Inc. Effervescent stannous fluoride tablet
US4613497A (en) 1984-02-29 1986-09-23 Health Products Development, Inc. Dry, water-foamable pharmaceutical compositions
US4725427A (en) 1984-03-13 1988-02-16 Albion International, Inc. Effervescent vitamin-mineral granule preparation
GB8421226D0 (en) 1984-08-21 1984-09-26 Int Conferences Ab Tooth cleaning tablet
US4639368A (en) 1984-08-23 1987-01-27 Farmacon Research Corporation Chewing gum containing a medicament and taste maskers
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4639458A (en) 1985-01-22 1987-01-27 Merck & Co., Inc. Tablet and formulation
JPS61183219A (ja) 1985-02-07 1986-08-15 Takeda Chem Ind Ltd 発泡組成物の製造法
US4687662A (en) 1985-08-30 1987-08-18 Warner-Lambert Company Therapeutic effervescent composition
US4797275A (en) 1985-09-26 1989-01-10 Eli Lilly And Company Nicarbazin feed premix
GB8724763D0 (en) 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
GB8909793D0 (en) 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
FR2653013B1 (fr) 1989-10-13 1992-01-10 Oreal Procede de preparation d'une solution aqueuse effervescente ayant une action emolliente sur la cuticule des ongles, composition pour la mise en óoeuvre dudit procede et traitement cosmetique correspondant.
EP0443381B2 (de) * 1990-02-14 1997-10-22 Takeda Chemical Industries, Ltd. Brausemischung, deren Herstellung sowie Verwendung
JP3180359B2 (ja) * 1991-02-28 2001-06-25 日本曹達株式会社 錠剤様発泡性農薬組成物の製造法
RU2096955C1 (ru) * 1991-03-01 1997-11-27 Е.И.Дюпон Де Немур Энд Компани Вододиспергируемая гранулированная пестицидная композиция, получаемая методом экструзии, и способ ее получения
GB2307857B (en) * 1995-12-04 1999-01-27 Euro Celtique Sa An effervescent formulation
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
DE19822036A1 (de) * 1998-05-15 1999-11-18 Bayer Ag Brausezubereitungen
GB2355511A (en) 1999-07-15 2001-04-25 Air Prod & Chem Freezing products

Also Published As

Publication number Publication date
ZA200208456B (en) 2003-10-20
SK15102002A3 (sk) 2003-06-03
CN1437462A (zh) 2003-08-20
AU5482601A (en) 2001-11-07
CZ20023419A3 (cs) 2003-05-14
KR20030011829A (ko) 2003-02-11
NO20024947L (no) 2002-12-12
CA2406833A1 (en) 2001-11-01
WO2001080822A3 (en) 2002-03-28
BG65877B1 (bg) 2010-04-30
NO333395B1 (no) 2013-05-27
IL152317A0 (en) 2003-05-29
HU230267B1 (hu) 2015-11-30
EP1274398B1 (de) 2008-10-08
CN100337613C (zh) 2007-09-19
HUP0300432A2 (hu) 2003-07-28
BG107193A (bg) 2003-06-30
HUP0300432A3 (en) 2005-02-28
DE60136057D1 (de) 2008-11-20
JP2003531161A (ja) 2003-10-21
MXPA02010338A (es) 2003-12-11
WO2001080822A2 (en) 2001-11-01
EP1274398A2 (de) 2003-01-15
IL152317A (en) 2010-05-31
DK1274398T3 (da) 2009-02-16
AU2001254826B2 (en) 2006-03-16
CA2406833C (en) 2009-06-30
SK287187B6 (sk) 2010-02-08
US6649186B1 (en) 2003-11-18
NO20024947D0 (no) 2002-10-15
JP5063848B2 (ja) 2012-10-31

Similar Documents

Publication Publication Date Title
ATE410145T1 (de) Herstellungsverfahren für brausegranulate
HK1066810A1 (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
MXPA04001037A (es) Derivados de n-fenilpirrol guanidina como ligandos del receptor de melanocortina.
IL155702A0 (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor
MXPA03008754A (es) Derivados de piridina fundidos para utilizarse como agonistas receptores vaniloide para tratar dolor.
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
MY137535A (en) New pyrrolidinium derivatives
BG108495A (en) 5-ht receptor ligands and uses thereof
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
NZ552137A (en) New 4-benzylidene-piperidin derivatives
GB0426313D0 (en) Therapeutic agents
YU39803A (sh) Jedinjenja piperazinilpirazina kao agonisti ili antagonisti serotonin 5ht-2-receptora
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
WO2002030870A3 (de) Substituierte c-cyclohexylmethylamin-derivate
BR0115121A (pt) Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas
RS20060072A (en) Aminoquinoline derivatives and their use as adenosine a3 ligands
SG151288A1 (en) 3-cyano-quinoline derivatives with antiproliferative activity
NZ530587A (en) Diazacycloalkanes as oxytocin agonists
MXPA03011158A (es) Estructura de solucion de il - 13 y sus usos.
NZ513041A (en) N-triazolylmethyl-piperazine derivatives as neurokinin receptor antagonists; their preparation and medicaments containing them
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
WO2001049651A3 (de) Aminomethyl-phenyl-cyclohexanonderivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties